Similar articles for PMID: 27713574

Year	Number of Results
2007	3
2008	2
2010	1
2011	2
2012	1
2013	3
2014	2
2015	3
2016	20
2017	15
2024	0

1

Structural insights into conformational stability of both wild-type and mutant EZH2 receptor.

Aier I, Varadwaj PK, Raj U. Aier I, et al. Sci Rep. 2016 Oct 7;6:34984. doi: 10.1038/srep34984. Sci Rep. 2016. PMID: 27713574 Free PMC article.

2

Polycomb repressive complex's evolutionary conserved function: the role of EZH2 status and cellular background.

Gall Trošelj K, Novak Kujundzic R, Ugarkovic D. Gall Trošelj K, et al. Clin Epigenetics. 2016 May 27;8:55. doi: 10.1186/s13148-016-0226-1. eCollection 2016. Clin Epigenetics. 2016. PMID: 27239242 Free PMC article. Review.

3

Semi-Quantitative Mass Spectrometry in AML Cells Identifies New Non-Genomic Targets of the EZH2 Methyltransferase.

Sbirkov Y, Kwok C, Bhamra A, Thompson AJ, Gil V, Zelent A, Petrie K. Sbirkov Y, et al. Int J Mol Sci. 2017 Jul 5;18(7):1440. doi: 10.3390/ijms18071440. Int J Mol Sci. 2017. PMID: 28678185 Free PMC article.

4

Enhancer of zeste homolog 2 depletion induces cellular senescence via histone demethylation along the INK4/ARF locus.

Jie B, Weilong C, Ming C, Fei X, Xinghua L, Junhua C, Guobin W, Kaixiong T, Xiaoming S. Jie B, et al. Int J Biochem Cell Biol. 2015 Aug;65:104-12. doi: 10.1016/j.biocel.2015.05.011. Epub 2015 May 22. Int J Biochem Cell Biol. 2015. PMID: 26004298

5

A687V EZH2 is a gain-of-function mutation found in lymphoma patients.

Majer CR, Jin L, Scott MP, Knutson SK, Kuntz KW, Keilhack H, Smith JJ, Moyer MP, Richon VM, Copeland RA, Wigle TJ. Majer CR, et al. FEBS Lett. 2012 Sep 21;586(19):3448-51. doi: 10.1016/j.febslet.2012.07.066. Epub 2012 Jul 28. FEBS Lett. 2012. PMID: 22850114 Free article.

6

EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?

Yan KS, Lin CY, Liao TW, Peng CM, Lee SC, Liu YJ, Chan WP, Chou RH. Yan KS, et al. Int J Mol Sci. 2017 May 31;18(6):1172. doi: 10.3390/ijms18061172. Int J Mol Sci. 2017. PMID: 28561778 Free PMC article. Review.

7

An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation.

Souroullas GP, Jeck WR, Parker JS, Simon JM, Liu JY, Paulk J, Xiong J, Clark KS, Fedoriw Y, Qi J, Burd CE, Bradner JE, Sharpless NE. Souroullas GP, et al. Nat Med. 2016 Jun;22(6):632-40. doi: 10.1038/nm.4092. Epub 2016 May 2. Nat Med. 2016. PMID: 27135738 Free PMC article.

8

Biophysical characterization of histone H3.3 K27M point mutation.

Hetey S, Boros-Oláh B, Kuik-Rózsa T, Li Q, Karányi Z, Szabó Z, Roszik J, Szalóki N, Vámosi G, Tóth K, Székvölgyi L. Hetey S, et al. Biochem Biophys Res Commun. 2017 Aug 26;490(3):868-875. doi: 10.1016/j.bbrc.2017.06.133. Epub 2017 Jun 21. Biochem Biophys Res Commun. 2017. PMID: 28647357 Free article.

9

Multifaceted role of the polycomb-group gene EZH2 in hematological malignancies.

Sashida G, Iwama A. Sashida G, et al. Int J Hematol. 2017 Jan;105(1):23-30. doi: 10.1007/s12185-016-2124-x. Epub 2016 Nov 9. Int J Hematol. 2017. PMID: 27830540 Review.

10

Enhancer of zeste homolog 2 downregulates E-cadherin by mediating histone H3 methylation in gastric cancer cells.

Fujii S, Ochiai A. Fujii S, et al. Cancer Sci. 2008 Apr;99(4):738-46. doi: 10.1111/j.1349-7006.2008.00743.x. Cancer Sci. 2008. PMID: 18377425 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

46 results

Results by year